ResearcherSeoul National UniversityActive in the last 2 years
Jae Hyup Jung
Matched on ORCID iD 0000-0002-6425-9682; OpenAlex author ID A5028220845. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 13
2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper
Papers 5
- Analysis of Recent Improvement of Survival Outcomes in Patients with Pancreatic Cancer Who Underwent Upfront Surgery. Co-author DOI 10.5009/gnl230303↗
- Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evidence-mapping, and meta-analysis. Co-author DOI 10.1177/17588359231175441↗
- Induction FOLFIRINOX followed by stereotactic body radiation therapy in locally advanced pancreatic cancer. Co-author DOI 10.3389/fonc.2022.1050070↗
- Clinical Impact of Unexpected Para-Aortic Lymph Node Metastasis in Surgery for Resectable Pancreatic Cancer. Co-author DOI 10.3390/cancers13174454↗
- Primary Granulocyte Colony-Stimulating Factor Prophylaxis in Metastatic Pancreatic Cancer Patients Treated with FOLFIRINOX as the First-Line Treatment. Co-author DOI 10.3390/cancers12113137↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jin‐Hyeok Hwang · 4 shared papers, 2020–2024 · strength 0.68
- Paper Analysis of Recent Improvement of Survival Outcomes in Patients with Pancreatic Cancer Who Underwent Upfront Surgery. DOI 10.5009/gnl230303↗
- Paper Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evi… DOI 10.1177/17588359231175441↗
- Paper Induction FOLFIRINOX followed by stereotactic body radiation therapy in locally advanced pancreatic cancer. DOI 10.3389/fonc.2022.1050070↗
- Jaihwan Kim · 4 shared papers, 2020–2024 · strength 0.68
- Paper Analysis of Recent Improvement of Survival Outcomes in Patients with Pancreatic Cancer Who Underwent Upfront Surgery. DOI 10.5009/gnl230303↗
- Paper Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evi… DOI 10.1177/17588359231175441↗
- Paper Induction FOLFIRINOX followed by stereotactic body radiation therapy in locally advanced pancreatic cancer. DOI 10.3389/fonc.2022.1050070↗
- Kwangrok Jung · 4 shared papers, 2021–2024 · strength 0.66
- Paper Analysis of Recent Improvement of Survival Outcomes in Patients with Pancreatic Cancer Who Underwent Upfront Surgery. DOI 10.5009/gnl230303↗
- Paper Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evi… DOI 10.1177/17588359231175441↗
- Paper Induction FOLFIRINOX followed by stereotactic body radiation therapy in locally advanced pancreatic cancer. DOI 10.3389/fonc.2022.1050070↗
- Jong-Chan Lee · 4 shared papers, 2020–2024 · strength 0.65
- Paper Analysis of Recent Improvement of Survival Outcomes in Patients with Pancreatic Cancer Who Underwent Upfront Surgery. DOI 10.5009/gnl230303↗
- Paper Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evi… DOI 10.1177/17588359231175441↗
- Paper Primary Granulocyte Colony-Stimulating Factor Prophylaxis in Metastatic Pancreatic Cancer Patients Treated with FOLFIRI… DOI 10.3390/cancers12113137↗
- Yoo‐Seok Yoon · 2 shared papers, 2021–2024 · strength 0.33
- Jun Suh Lee · 2 shared papers, 2021–2024 · strength 0.33
- Ho‐Seong Han · 2 shared papers, 2021–2024 · strength 0.33
- Jinwoo Ahn · 2 shared papers, 2022–2023 · strength 0.33
- Paper Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evi… DOI 10.1177/17588359231175441↗
- Paper Induction FOLFIRINOX followed by stereotactic body radiation therapy in locally advanced pancreatic cancer. DOI 10.3389/fonc.2022.1050070↗
- Jin Won Kim · 1 shared paper, 2024 · strength 0.21
- Bo‐Mi Kim · 1 shared paper, 2023 · strength 0.17
- Jong-chan Lee · 1 shared paper, 2022 · strength 0.16
- Dong Woo Shin · 1 shared paper, 2020 · strength 0.15
- Ho-Kyoung Lee · 1 shared paper, 2021 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.